Trial · NCT07905417
Effects of Posterior Capsular Stretching With and Without Dynamic Neuromuscular Stabilization Exercises in Frozen Shoulder
NCT07905417, Not applicable, Not yet recruiting, University of Management and Technology Lahore
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Posterior Capsular Stretching With and Without Dynamic Neuromuscular Stabilization Exercises in Frozen Shoulder. Trials, record NCT07905417. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905417
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Posterior Capsular Stretching With and Without Dynamic Neuromuscular Stabilization Exercises in Frozen Shoulder
- NCT number
- NCT07905417
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- University of Management and Technology Lahore
- Conditions
- Frozen Shoulder
- Interventions
- Posterior Capsular Stretching with Dynamic Neuromuscular Stabilization, Posterior Capsular Stretching
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Numeric Rating Scale (NPRS) | Baseline and 6 weeks | Numeric Rating Scale (NPRS) is most frequently used instruments to measure pain intensity in low back pain (LBP).The 11-point numeric with 0 representing No pain, 1-3 representing Mild Pain (nagging, annoying, interfering little with ADLs), 4-6 representing Moderate Pains (interferes significantly with ADLs), 7-10 representing Sever Pain (disabling, unable to perform ADLs) |
| Primary | MUSCULOSKELETAL ULTRASOUND (AXILLARY POUCH CAPSULE THICKNESS MEASUREMENT) | Baseline and 6 weeks | Musculoskeletal ultrasound has emerged as a valuable imaging modality due to its affordability, portability, absence of ionizing radiation, and capacity for dynamic, real-time assessment at the point of care. The Axillary pouch capsule is the inferior part of the glenohumeral capsule located between the anterior and posterior bands of the inferior glenohumeral ligament (IGHL) The presence of AP thickening will be carefully investigated using the axillary approach and its maximum thickness will be measured with the arm abducted 70 -90 in neutral rotation. The long axis of the transducer will be applied on the axilla along the long axis of the humeral head/neck, then anterior and posterior sliding of the transducer will be done to pick up the maximal obtainable thickening. The axillary pouch thickness will be measured from the humeral neck cortex to the outer margin of the capsule. A high-frequency linear array transducer (7.5-14 MHz) will be used for musculoskeletal assessment. It will |
| Primary | SHOULDER PAIN AND DISABILITY INDEX (SPADI) | Baseline and 6 weeks | The Shoulder Pain and Disability Index (SPADI) is a self-administered questionnaire that consists of two dimensions: pain (5 items) and disability (8 items). Each item is scored on a visual analog scale from 0 to 10, where 0 indicates no pain/no difficulty and 10 indicates worst imaginable pain/so difficult requires help. The total score ranges from 0 to 100, with higher scores indicating greater pain and disability. The SPADI has been shown to have good reliability, validity, and responsiveness in patients with shoulder disorders including adhesive capsulitis |
| Primary | INTERNAL ROTATION DEFICIT MESAUREMENT | Baseline and 6 weeks | GIRD defined by a loss of \>20° of IR compared to the contralateral shoulder(23) A difference of 20° or more when compared to the contralateral side is generally considered diagnostic of GIRD. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905417
GET https://conductscience.org/api/trials/v1/NCT07905417/registered